Comparative cardiovascular safety of strontium ranelate and bisphosphonates amongst patients with no contraindications: A multi‐database study in 5 EU countries by the EU‐ADR Alliance

Aug-18

AUTHORS : Dr M.Sanni Ali, Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Botnar Research Centre, Windmill Road , Oxford OX3 7LD , UK – Email: sanni.ali@lshtm.ac.uk / sanni.ali@ndorms.ox.ac.uk – Profile: https://www.medsci.ox.ac.uk/study/graduateschool/supervisors/sanni-ali – Cannot find more information for his affiliation to London School of Hygiene and Tropical Medicine apart from email details from another study

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 27(S2):186-187

DOI : 10.1002/pds.4629

Comparative cardiovascular safety of strontium ranelate and bisphosphonates amongst patients with no contraindications: A multi‐database study in 5 EU countries by the EU‐ADR Alliance

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study